Matthew Farley

Matthew Farley

Expertise: Fundamental Analysis, Technical Analysis

Education: Bachelor of Business Studies, Economics, Auckland University

Awards & Accomplishments: Financial Modeling & Valuation Analyst (FMVA)

Matthew Farley is a stock analyst and journalist who aims to bring a rational voice to the financial markets. He has written for publications such as the Motley Fool, Seeking Alpha, and New Scientist magazine, among others. Matthew has a particular interest in creating low-volatility portfolios and dividend investing.

Matthew spent most of his career in financial technology startups before he began writing about the markets in 2018. As such, he is long on cryptocurrencies and related Web 3.0 technologies, AI, large language models (LLM), and other disruptive platforms that are leading humanity forward.

Matthew’s investment philosophy is to build wealth slowly, preserve capital, and let compounding do the heavy lifting for you. As such, he owns shares in many blue-chip, established “boring” companies that have been around for decades with some adventurous incursions thrown into risky moonshots (as he’s still young).

Recent Articles

3 Space Stocks to Turn $100,000 Into $1 Million: April 2024

Explore three space stocks that could turn $100,000 into $1 million. Uncover the potential for significant returns.

7 Semiconductor Stocks to Turn $100,000 Into $1 Million: April 2024

Discover seven semiconductor stocks set to transform $100,000 into $1 million. Dive into this opportunity for substantial growth.

The 3 Most Undervalued Flying Car Stocks to Buy in April 2024

Uncover three undervalued flying car stocks poised for dramatic growth. These picks could be the key to unlocking significant returns.

If You Can Only Buy One Space Stock in April, It Better Be One of These 3 Names

Discover the space stocks set to rocket in April, offering unique investment opportunities across aerospace, tourism, and communication.

3 Pharma Stocks to Sell in April Before They Crash & Burn

Discover three pharma stocks to sell in April, facing challenges and signaling potential for significant downside.